Market Cap 47.13M
Revenue (ttm) 37.87M
Net Income (ttm) -6.48M
EPS (ttm) N/A
PE Ratio 37.89
Forward PE N/A
Profit Margin -17.11%
Debt to Equity Ratio 0.18
Volume 120,600
Avg Vol 64,478
Day's Range N/A - N/A
Shares Out 14.96M
Stochastic %K 27%
Beta -0.39
Analysts Strong Buy
Price Target $8.50

Company Profile

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, an...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 615 255 0068
Fax: 615 255 0094
Address:
1600 West End Avenue, Suite 1300, Nashville, United States
Dogfon
Dogfon Jul. 5 at 6:05 AM
$CPIX Duchenne Muscular Dystrophy (DMD) Cardiomyopathy – Dyscorban®
0 · Reply
Dogfon
Dogfon Jul. 5 at 5:35 AM
$CPIX brand name selected Duchenne Muscular Dystrophy (DMD) Cardiomyopathy – Dyscorban® Interesting
0 · Reply
EyeLuv69
EyeLuv69 Jul. 3 at 2:34 PM
$CPIX The problem with this stock is it is illiquid. Most of the shares are tightly held by insiders, and they don't dilute to add more shares to the flow. It is hard for tutes to buy or even small investors have challenges to buy or sell without moving SP. Any drops can potentially trigger stop-loss orders and cause huge drops. This baby is not for the faint-hearted (warning :-))
0 · Reply
FeliciaMath
FeliciaMath Jul. 2 at 10:13 PM
decided to sell $CPIX today at 3.41/made 30% gain $600
0 · Reply
EyeLuv69
EyeLuv69 Jul. 2 at 6:34 PM
$CPIX Interesting fact: They may have 41 patients on their OLE Trial. That would be one heck of a dataset for OLE, If that data is good, it would be very convincing to FDA that this drug works. IMHO. Here is the reasoning: At the end of Phase 2, there were 41 patients completed the trial in total. Assuming none of the patients quit OLE, then there would be 41 in OLE at the end (Mid 2025). Here is a snaphot of the Trial 2 years ago, and there were already 24 patients on OLE. All patients decided to join OLE. Maybe they know it works because this is an open label, the data is known during the trial.
0 · Reply
EyeLuv69
EyeLuv69 Jul. 2 at 1:01 PM
$CPIX It seems we may see $20 by year end ! Management should know the result of the OLE Trial already because it is open label by now, and the data must be very good because the CEO just said: "We're optimistic about taking the next step toward bringing this much-needed treatment to DMD patients and their families." In fact, they should know it along the way just like CAPR kept reporting 1-year, 2-year, 3 -year, and 4-year OLE data along the way.
0 · Reply
FeliciaMath
FeliciaMath Jul. 2 at 1:20 AM
put a SL on $CPIX at 3.3 - if that hits, i'll take 26% gain/$519 and move on. really have to think about it cause it can go to 6. THINKING.
0 · Reply
EyeLuv69
EyeLuv69 Jul. 1 at 2:32 PM
0 · Reply
peapope
peapope Jul. 1 at 2:31 PM
$CPIX seeing the positive divergence with Capr glta longs
0 · Reply
EyeLuv69
EyeLuv69 Jul. 1 at 2:24 PM
$CPIX Management will announce 3-year OLE data soon, Mid-2025 is "now" :-) Then they will seek Accelerated Approval (Just my guessing), because they qualify for it. Keep in mind that for rare diseases, Phase 3 Confirmation trial does not necessarily need to be underway especially DMD is considered as Ultra-Rare disease (not just rare).
0 · Reply
Latest News on CPIX
VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA

Feb 18, 2025, 7:30 AM EST - 4 months ago

VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA


FDA APPROVES ACETADOTE® sNDA

Dec 9, 2024, 4:05 PM EST - 7 months ago

FDA APPROVES ACETADOTE® sNDA


Cumberland Pharmaceuticals Reports 41% Revenue Growth

Nov 8, 2022, 4:05 PM EST - 2 years ago

Cumberland Pharmaceuticals Reports 41% Revenue Growth


Dogfon
Dogfon Jul. 5 at 6:05 AM
$CPIX Duchenne Muscular Dystrophy (DMD) Cardiomyopathy – Dyscorban®
0 · Reply
Dogfon
Dogfon Jul. 5 at 5:35 AM
$CPIX brand name selected Duchenne Muscular Dystrophy (DMD) Cardiomyopathy – Dyscorban® Interesting
0 · Reply
EyeLuv69
EyeLuv69 Jul. 3 at 2:34 PM
$CPIX The problem with this stock is it is illiquid. Most of the shares are tightly held by insiders, and they don't dilute to add more shares to the flow. It is hard for tutes to buy or even small investors have challenges to buy or sell without moving SP. Any drops can potentially trigger stop-loss orders and cause huge drops. This baby is not for the faint-hearted (warning :-))
0 · Reply
FeliciaMath
FeliciaMath Jul. 2 at 10:13 PM
decided to sell $CPIX today at 3.41/made 30% gain $600
0 · Reply
EyeLuv69
EyeLuv69 Jul. 2 at 6:34 PM
$CPIX Interesting fact: They may have 41 patients on their OLE Trial. That would be one heck of a dataset for OLE, If that data is good, it would be very convincing to FDA that this drug works. IMHO. Here is the reasoning: At the end of Phase 2, there were 41 patients completed the trial in total. Assuming none of the patients quit OLE, then there would be 41 in OLE at the end (Mid 2025). Here is a snaphot of the Trial 2 years ago, and there were already 24 patients on OLE. All patients decided to join OLE. Maybe they know it works because this is an open label, the data is known during the trial.
0 · Reply
EyeLuv69
EyeLuv69 Jul. 2 at 1:01 PM
$CPIX It seems we may see $20 by year end ! Management should know the result of the OLE Trial already because it is open label by now, and the data must be very good because the CEO just said: "We're optimistic about taking the next step toward bringing this much-needed treatment to DMD patients and their families." In fact, they should know it along the way just like CAPR kept reporting 1-year, 2-year, 3 -year, and 4-year OLE data along the way.
0 · Reply
FeliciaMath
FeliciaMath Jul. 2 at 1:20 AM
put a SL on $CPIX at 3.3 - if that hits, i'll take 26% gain/$519 and move on. really have to think about it cause it can go to 6. THINKING.
0 · Reply
EyeLuv69
EyeLuv69 Jul. 1 at 2:32 PM
0 · Reply
peapope
peapope Jul. 1 at 2:31 PM
$CPIX seeing the positive divergence with Capr glta longs
0 · Reply
EyeLuv69
EyeLuv69 Jul. 1 at 2:24 PM
$CPIX Management will announce 3-year OLE data soon, Mid-2025 is "now" :-) Then they will seek Accelerated Approval (Just my guessing), because they qualify for it. Keep in mind that for rare diseases, Phase 3 Confirmation trial does not necessarily need to be underway especially DMD is considered as Ultra-Rare disease (not just rare).
0 · Reply
EyeLuv69
EyeLuv69 Jul. 1 at 2:12 PM
$CPIX Even though Management has never mentioned about Accelerated Approval pathway. This conservative Management will never reveal their intention until after phase-2 review with FDA. IMHO. But, according to Management, They will announce 3-year OLE data soon (Mid 2025), They only need 3-year OLE data if they are going to seek Accelerated Approval pathway. IMHO. From last PPMD Conference
0 · Reply
EyeLuv69
EyeLuv69 Jul. 1 at 1:58 PM
$CPIX CPIX's latest data analysis presented in last PPMD conference show CPIX's drug significantly reduce the 2 main biomarkers for heart damage/failure: Note: NT-proBNP can be one of the surrogate endpoints for DMD cardiomyopathy. (needed for Accelerate Approval)
0 · Reply
EyeLuv69
EyeLuv69 Jul. 1 at 1:14 PM
$CPIX Some folks on CAPR board has very good DD, I think it is worthy for CPIX's investor to know: It is true that FDA and other Gov agents gave grants to Dr. Jonathan Soslow (Vanderbilt U.) to collaborate with other renowned specialists around US to establish the guideline for DMD cardiomyopathy trials surrogate endpoints and endpoints. Dr. Jonathan Soslow is a renowned doctor in US specializing in DMD Cardiac MRI imaging. He is also the co-investigator for CPIX's DMD trial and he did the imaging for CPIX' DMD trial. The conclusion is these 2 can be used as endpoint for FDA guideline: 1) LVEF - Left Ventricular Ejection Fraction 2) NT-proBNP - biomarker
0 · Reply
peapope
peapope Jun. 30 at 8:31 PM
0 · Reply
peapope
peapope Jun. 30 at 5:49 PM
$CPIX bot some back at 2.75ish looks good I still wonder about the Cpix/Capr comparisons
1 · Reply
2pumps1dump
2pumps1dump Jun. 30 at 5:39 PM
$CPIX 👀
0 · Reply
peapope
peapope Jun. 30 at 5:35 PM
$CPIX not a bad move up company has real fundamentals. The DD data was the same could that downturn have been manipulated?
0 · Reply
EyeLuv69
EyeLuv69 Jun. 30 at 3:06 PM
$CPIX I borrowed money from my brother who just have his CDs expired, so I bought more shares at this fire-sale level. Adding 30K more over last few days. This will be my last post until this stock makes new highs. I will be back when this gem makes new highs Do your own DD, and good luck to all $100+
1 · Reply
EyeLuv69
EyeLuv69 Jun. 30 at 2:57 PM
$CPIX I am out
1 · Reply
ripztrip
ripztrip Jun. 29 at 3:17 AM
$CPIX this is toral trash & garbage
1 · Reply
FeliciaMath
FeliciaMath Jun. 27 at 4:32 PM
bought $CPIX today at 2.62
0 · Reply
Remwmberthebull
Remwmberthebull Jun. 27 at 7:31 AM
$CPIX @Prager you still here? Need your thoughts and wisdom?
1 · Reply